Navigation Links
EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
Date:6/3/2008

Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients

ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of clinical data for the MKC-1 Phase 2 study in patients with metastatic breast cancer. The data were presented by Bryan P. Schneider, M.D., Assistant Professor, Department of Medicine, Indiana University, during the Breast Cancer -- Metastatic session at the American Society of Clinical Oncology Annual Meeting being held this week in Chicago, Illinois.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

For this Phase 2 single agent, open label study, a total of 65 patients who had previously received at least one anthracycline and taxane therapy were enrolled. 55 patients were evaluable for tumor response. Of the evaluable patients, the antitumor activity observed with MKC-1 included 3 patients who had responses and 5 patients with stable disease lasting more than four months.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Data from previous studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. To date, MKC-1 has been evaluated in over 400 patients in multiple Phase 1 and 2 clinical trials.

Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medic
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
2. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
3. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
4. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
8. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
9. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
10. EntreMed Raises $20 Million to Support Clinical Development Program
11. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...  Decision Resources, one of the world,s leading ... issues, finds that, for the treatment of rheumatoid ... rheumatologists cite a therapy,s induction of remission as ... prescribing decisions. Over 60 percent and 70 percent ... percentage of patients achieving remission at six months ...
(Date:6/19/2013)... JOSE, Calif. , June 19, 2013 BD ... BDX ), a leading global medical technology company, ... Cell Analyzer , the latest in its line of high-performance ... Cell Analyzer delivers high-performance multicolor analysis with the most compact ... X 73.7 cm) and a height of 30" (76.2 cm). ...
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- In ... new specialty pharmaceutical company dedicated to advancing ... injectable and sustained release drug therapies in ... needs, today announced the acquisition of Enzon ... platform and associated product pipeline. Acquisition of ...
Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
(Date:6/19/2013)... 2013 Dental professionals are increasingly monitoring ... minor to moderate sedation, a patient’s breathing depth and ... is the latest to update its guidelines to require ... in an effort to increase safety in procedures. This ... Act goes into effect July 1. , The ...
(Date:6/19/2013)... June 19, 2013 DiscountFurnaceFilter.com, the number one ... offer the 5-2-1 Compressor Saver kit at an exceptional price. ... Kit) aids the air conditioning unit during start up, saving ... air compressor or unit burn out. , The 5-2-1 ... the air conditioner uses less power to start and drastically ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Guests at the ... wealthy and wise even if they don’t go to bed ... require some early thought. , Crafty travelers ... they take advantage of the pet-friendly Scottsdale Paradise Valley hotel’s ... . With at least 14 days advance notice, guests can ...
(Date:6/19/2013)... Washington (PRWEB) June 19, 2013 ... physicians deem it medically necessary, according to a ... and Child Health Journal. The results of this ... for more than a decade – that trying-to-conceive ... and maintaining a healthy body weight. Fairhaven Health ...
(Date:6/19/2013)... The motor neuron disease Amyotrophic lateral sclerosis (ALS), also ... sequential pattern which can be classified into four distinct ... at the University of Pennsylvania in the Annals ... and spinal cord tissues shows, for the first time, ... starting point in the central nervous system to other ...
Breaking Medicine News(10 mins):Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2
... dedicated to the health and well being of children, ... (FDA) has approved an investigational new drug application; ... topical solution for the treatment of head lice. ... professionals a new choice for the treatment of head ...
... cyclists will be participating in the Memory Ride for Alzheimer's ... to fight the disease that affects more than 5 ... 11th annual Memory Ride has a personal story to tell ... who has struggled with the disease. ,The Alzheimer's ...
... is not as squeaky-clean as she appears . ,In a ... she is quite the opposite of her supposed righteous image. ... Do you think you have a squeaky-clean image? Im like, Could ... Us Weekly quoted her, as telling the mag. ,I ...
... the University of Idaho is helping to increase understanding ... identify conditions that make women prone to infections and ... problems. ,Women suffer from insidious health problems, ... send them in droves to seek medical treatment, said ...
... the occurrence of anaphylaxis between the northern and southern ... be fatal without treatment with epinephrine. The striking ... risk, currently are without explanation. The investigators hypothesize, however, ... sunshine, may play a role and that this hypothesis ...
... can relieve people of shyness, and help them socialise with ... use, and an individual can boost self-confidence just by squirting ... that the spray harnesses the powers of a feel-good hormone ... in social recognition and bonding. ,The mammalian ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Large Geographic Differences in EpiPen Prescriptions in the U. S. 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: